Cerevance takes funding haul to $98m to fight Parkinson's and other CNS disorders
Boston US life science company Cerevance, which has facilities at Cambridge Science Park, has taken its Series B-1 round to a stunning $98 million after securing a $47m extension.
Campbell Murray Kouki Harasaki Craig Thompson Netsseq Nuclear Enriched Transcript Sort Agent Capital Bioluminescence Ventures
Source: businessweekly.co.uk